PMC:6537946 / 11330-13174 JSON TXT

Annnotations TAB JSON ListView MergeView

0_colil

{"project":"0_colil","denotations":[{"id":"31106338-24262348-6281","span":{"begin":144,"end":146},"obj":"24262348"},{"id":"31106338-11794191-6282","span":{"begin":479,"end":481},"obj":"11794191"},{"id":"31106338-19038734-6283","span":{"begin":913,"end":915},"obj":"19038734"}],"text":"Ventricular assist devices (VADs) evolved from research involving cardiopulmonary bypass and the total artificial heart in the 1950s and 1960s [32]. With publication of the REMATCH (Randomized Evaluation of Mechanical Assistance for the Treatment of Congestive Heart Failure) trial in 2001, the VAD breakthrough began following demonstration of the longer survival of heart failure candidates with VAD support in comparison to those treated with optimal medical treatment alone [33]. Increasing numbers of VAD implants are currently designated as destination therapy, although some of them were primarily implanted with a bridge-to-transplant intention. In a patient with a stabilized cardiac condition, this VAD support might frequently make further high-urgency listings for transplants superfluous, or patients do not fulfil strict heart transplant high-urgency criteria or simply no longer want a transplant [34]. Independently of the excellent long-term data for heart transplants, patients who are denied a transplant (due to older age or relevant comorbidities) or who will not survive the long high-urgency waiting time might benefit most from a permanent LVAD and attain outpatient status with acceptable quality of life (QoL) for a certain period. One current trial is examining the optimal point to implant a VAD in patients who have been given transplantable (T−) status and who are listed for a heart transplant with an increased risk of death while on the waiting list. The study was designed to compare the superiority of an early VAD implant to the current therapeutic strategy of medical heart failure treatment and assist device implantation only after serious deterioration of the patient’s condition. Final data collection for primary outcome measures is expected in August 2022 (ClinicalTrials.gov Identifier: NCT02387112)."}

TEST0

{"project":"TEST0","denotations":[{"id":"31106338-144-150-6281","span":{"begin":144,"end":146},"obj":"[\"24262348\"]"},{"id":"31106338-232-238-6282","span":{"begin":479,"end":481},"obj":"[\"11794191\"]"},{"id":"31106338-228-234-6283","span":{"begin":913,"end":915},"obj":"[\"19038734\"]"}],"text":"Ventricular assist devices (VADs) evolved from research involving cardiopulmonary bypass and the total artificial heart in the 1950s and 1960s [32]. With publication of the REMATCH (Randomized Evaluation of Mechanical Assistance for the Treatment of Congestive Heart Failure) trial in 2001, the VAD breakthrough began following demonstration of the longer survival of heart failure candidates with VAD support in comparison to those treated with optimal medical treatment alone [33]. Increasing numbers of VAD implants are currently designated as destination therapy, although some of them were primarily implanted with a bridge-to-transplant intention. In a patient with a stabilized cardiac condition, this VAD support might frequently make further high-urgency listings for transplants superfluous, or patients do not fulfil strict heart transplant high-urgency criteria or simply no longer want a transplant [34]. Independently of the excellent long-term data for heart transplants, patients who are denied a transplant (due to older age or relevant comorbidities) or who will not survive the long high-urgency waiting time might benefit most from a permanent LVAD and attain outpatient status with acceptable quality of life (QoL) for a certain period. One current trial is examining the optimal point to implant a VAD in patients who have been given transplantable (T−) status and who are listed for a heart transplant with an increased risk of death while on the waiting list. The study was designed to compare the superiority of an early VAD implant to the current therapeutic strategy of medical heart failure treatment and assist device implantation only after serious deterioration of the patient’s condition. Final data collection for primary outcome measures is expected in August 2022 (ClinicalTrials.gov Identifier: NCT02387112)."}

2_test

{"project":"2_test","denotations":[{"id":"31106338-24262348-28904594","span":{"begin":144,"end":146},"obj":"24262348"},{"id":"31106338-11794191-28904595","span":{"begin":479,"end":481},"obj":"11794191"},{"id":"31106338-19038734-28904596","span":{"begin":913,"end":915},"obj":"19038734"}],"text":"Ventricular assist devices (VADs) evolved from research involving cardiopulmonary bypass and the total artificial heart in the 1950s and 1960s [32]. With publication of the REMATCH (Randomized Evaluation of Mechanical Assistance for the Treatment of Congestive Heart Failure) trial in 2001, the VAD breakthrough began following demonstration of the longer survival of heart failure candidates with VAD support in comparison to those treated with optimal medical treatment alone [33]. Increasing numbers of VAD implants are currently designated as destination therapy, although some of them were primarily implanted with a bridge-to-transplant intention. In a patient with a stabilized cardiac condition, this VAD support might frequently make further high-urgency listings for transplants superfluous, or patients do not fulfil strict heart transplant high-urgency criteria or simply no longer want a transplant [34]. Independently of the excellent long-term data for heart transplants, patients who are denied a transplant (due to older age or relevant comorbidities) or who will not survive the long high-urgency waiting time might benefit most from a permanent LVAD and attain outpatient status with acceptable quality of life (QoL) for a certain period. One current trial is examining the optimal point to implant a VAD in patients who have been given transplantable (T−) status and who are listed for a heart transplant with an increased risk of death while on the waiting list. The study was designed to compare the superiority of an early VAD implant to the current therapeutic strategy of medical heart failure treatment and assist device implantation only after serious deterioration of the patient’s condition. Final data collection for primary outcome measures is expected in August 2022 (ClinicalTrials.gov Identifier: NCT02387112)."}

MyTest

{"project":"MyTest","denotations":[{"id":"31106338-24262348-28904594","span":{"begin":144,"end":146},"obj":"24262348"},{"id":"31106338-11794191-28904595","span":{"begin":479,"end":481},"obj":"11794191"},{"id":"31106338-19038734-28904596","span":{"begin":913,"end":915},"obj":"19038734"}],"namespaces":[{"prefix":"_base","uri":"https://www.uniprot.org/uniprot/testbase"},{"prefix":"UniProtKB","uri":"https://www.uniprot.org/uniprot/"},{"prefix":"uniprot","uri":"https://www.uniprot.org/uniprotkb/"}],"text":"Ventricular assist devices (VADs) evolved from research involving cardiopulmonary bypass and the total artificial heart in the 1950s and 1960s [32]. With publication of the REMATCH (Randomized Evaluation of Mechanical Assistance for the Treatment of Congestive Heart Failure) trial in 2001, the VAD breakthrough began following demonstration of the longer survival of heart failure candidates with VAD support in comparison to those treated with optimal medical treatment alone [33]. Increasing numbers of VAD implants are currently designated as destination therapy, although some of them were primarily implanted with a bridge-to-transplant intention. In a patient with a stabilized cardiac condition, this VAD support might frequently make further high-urgency listings for transplants superfluous, or patients do not fulfil strict heart transplant high-urgency criteria or simply no longer want a transplant [34]. Independently of the excellent long-term data for heart transplants, patients who are denied a transplant (due to older age or relevant comorbidities) or who will not survive the long high-urgency waiting time might benefit most from a permanent LVAD and attain outpatient status with acceptable quality of life (QoL) for a certain period. One current trial is examining the optimal point to implant a VAD in patients who have been given transplantable (T−) status and who are listed for a heart transplant with an increased risk of death while on the waiting list. The study was designed to compare the superiority of an early VAD implant to the current therapeutic strategy of medical heart failure treatment and assist device implantation only after serious deterioration of the patient’s condition. Final data collection for primary outcome measures is expected in August 2022 (ClinicalTrials.gov Identifier: NCT02387112)."}

testtesttest